Unlocking the language of the heart
Leveraging cutting-edge AI, industry-leading translational science and deep electrophysiological data to transform cardiac care
Anumana™ is an AI-driven health technology company from nference, building and commercializing AI solutions to improve patient care throughout the cardiac care continuum.
Our Impact
The Impact of AI Algorithms in Cardiology
Listen to Dr. Paul Friedman, a Professor of Medicine and Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Anumana advisor, discuss the potential of AI algorithms in advancing early diagnosis and intervention in cardiology.
Diagnostic Electrocardiography
Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate, at times resulting in life-threatening events. Anumana’s AI solutions enable earlier diagnosis of these otherwise hidden diseases, empowering clinicians to intervene with treatments earlier and improve outcomes.
Interventional Electrophysiology
Today, the power of AI is just beginning to be leveraged in EP clinical decision support and can provide immense value during EP procedures. Anumana’s algorithms and software have the potential to improve procedure accuracy, reduce procedure times, improve medication management, and improve patient safety and outcomes.
Why Us
Rich, Proprietary Data
Anumana has one of the world’s largest electrophysiological data and longitudinal patient history and outcomes in the world. This harmonized, cleaned, and validated dataset was developed from multi-year data partnerships with several health systems from Anumana’s parent company, nference. This real-world evidence generation platform, nSights, is inclusive of 11M patients spanning 20+ years and transforms unstructured data (i.e. clinical notes, echocardiogram reports) and semi-structured (i.e. lab tests, medications, appointments, etc) into labeled data format at scale. This extensive data platform is the basis upon which Anumana’s research is conducted.
Cutting-Edge AI Algorithms
Anumana develops state-of-the-art ECG-AI and EGM-AI algorithms which are rooted in science and backed by a growing body of data. The growing pipeline of ECG-AI algorithms have been validated by over 75 peer-reviewed publications, including The Lancet and Nature.
Innovative Software and Integrations
Anumana builds and commercializes clinician-facing software and solutions to democratize insights from its cardiology-AI. Anumana’s software solutions seamlessly integrate with EMRs and other point-of-care technology used within the clinician’s workflow.
Diagnostic Algorithm Pipeline
Innovative diagnostic tools for detecting rare and hidden disease, based on the world’s largest labeled patient dataset, built to be integrated into existing physician workflows and currently pursuing FDA approval.
Low Ejection Fraction
Granted FDA Breakthrough Device Designation
Phase: Validation
Pulmonary Hypertension
Granted FDA Breakthrough Device Designation
Phase: Pre-Submission
Hyperkalemia
Granted FDA Breakthrough Device Designation
Phase: Development
Cardiac Amyloidosis
Phase: Development
Atrial Fibrillation in Normal Sinus Rhythm
Phase: Development
Hypertrophic Cardiomyopathy
Phase: Development
Myocarditis
Phase: Development
Aortic Stenosis
Phase: Development
Early Stage Development Programs
Phase: Development
Interventional EP Product Pipeline
Anumana also has a rich pipeline of AI / ML driven products for use in the interventional electrophysiology (EP) setting.
Hardware Agnostic AI / ML based EAM Software
Phase: Authorization
EP Case Review Software
FDA Clearance Not Required
Phase: Submission
Signal Identification Software
Phase: Validation
Early Stage Development Programs
Phase: Development
News and Press Releases
See Anumana’s work in the news
Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics
FIERCE Biotech: The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help diagnose cases of cardiac amyloidosis, where misfolded proteins build up around the tissue.
Dec. 16th, 2022
Mayo Clinic spinout Anumana acquires NeuTrace to develop cardiac procedure AI
FIERCE Biotech: Mayo Clinic’s artificial intelligence spinout Anumana is taking a deeper dive into analyzing the pulsing electrical signals of the heart with a new acquisition aimed at developing software used during cardiac procedures.
Nov. 8th, 2022
Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Med City News: Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions years before symptoms develop in order to enable earlier intervention.
Jul. 14th, 2022
Our Science & Publications
Learn more about Anumana’s algorithms validated in 75+ peer reviewed publications.
Digitizing paper based ECG files to foster deep learning based analysis of existing clinical datasets: An exploratory analysis
Aug. 8th, 2022
Community-based participatory research application of an artificial intelligence-enhanced electrocardiogram for cardiovascular disease screening: A FAITH! Trial ancillary study
Nov. 13th, 2022
Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction
Nov. 14th, 2022
Clinician Adoption of an Artificial Intelligence Algorithm to Detect Left Ventricular Systolic Dysfunction in Primary Care.
Nov. 1st, 2022
In the Media
At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help...
In just the past three years, the team has published more than two dozen studies on AI in cardiology, and it is now field-testing an algorithm to detect a weak heart pump in dozens of primary care clinics.
Stat
Dec. 18th, 2019
Partner with us!
We’re actively developing algorithms for FDA approval. Please direct partnership and media inquiries to hello@anumana.ai
@2023 anumana, Inc. All rights reserved.